Skip to main content
. 2019 Jun 14;11(6):1343. doi: 10.3390/nu11061343

Figure 4.

Figure 4

Upregulation of SIRT1 attenuates IL-1β-induced ICAM-1 and VCAM-1 expression in GBM. (A) Messenger RNA levels of SIRT1 in glioma patient specimens obtained from GSE4290 datasets. The data are presented as mean ± S.E.M. **** p < 0.0001 grade II glioma group or non-tumor group compared with GBM group. *** p < 0.05 grade III glioma group compared with the GBM group. (B) GBM cells U251 and U87 were administrated with various concentrations of melatonin (0.25, 0.5 or 1 mM) for 24 h, and expression of SIRT1 was analyzed using western blot. (C) GBM cells U251 and U87 cells were treated with melatonin (0.5 mM) for different time periods (8, 16 or 24 h), and SIRT1 expression was analyzed using western blotting. Cells were pretreated with SIRT1 activator CAY10591 (5 μM) (D) or SIRT1 inhibitor EX527 (10 μM) (E) for 45 min then administrated with IL-1β (3 ng/mL) for another 24 h. The expression levels of SIRT1, ICAM-1 and VCAM-1 and expression was assessed using western blotting. (F) ALTS1C1 were transfected with wild-type SIRT1 or empty vector for 24 h and administrated with IL-1β (3 ng/mL) for another 24 h. The expression of VCAM-1 and SIRT1 were assessed using western blotting. The data are presented as mean ± S.E.M. (representative of independent experiments = 3). WT: wild type.